Phase 1Completed
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients
- Sponsor
- Theratechnologies (Industry)
- Enrollment
- 18 enrolled
- Conditions
- HIV
- Interventions
- Tesamorelin
- Ages
- adults, older adults
- Registry
- NCT02012556
Full record on ClinicalTrials.gov
From the registry
The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1) profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated administration once daily for 14 consecutive days. Secondary objectives include the evaluation of the safety and tolerability of tesamorelin following multiple subcutaneous injections.
Primary outcomes
- Area under the Plasma Concentration versus Time Curve (AUC) of Tesamorelin.
- Peak Plasma Concentration (Cmax) of Tesamorelin.
- Time to Maximum Plasma Concentration (Tmax) of Tesamorelin.
- Apparent Elimination Half-life (T1/2 el) of Tesamorelin.
History
Registered
Primary completion
Started